

CLEAN COPY OF SPECIFICATION AND CLAIMS AFTER AMENDMENT

In the Specification:

On page 1, the first full paragraph is amended, as follows:

D₁ This application is a continuation of application Serial. No. 08/624,374 which was filed on March 27, 1996, now U.S. Patent No. 6,063,620. That application, in turn, is the entry into the National Phase of International Application No. PCT/GB 94/021100 which was filed on September 27, 1994.

In the Claims:

Claims 1-7, 11, and 14-17 are canceled.

Claims 18 and 19 are amended, as follows:

Sub E1
D2
18. (Amended) A diagnostic test kit comprising a monoclonal antibody attached to a detectable label, wherein said monoclonal antibody binds specifically to a peptide having the amino acid sequence (SEQ ID. No. 1) $\text{H}_2\text{N}-\overset{\text{F}}{\text{Glu}}-\overset{\text{D}}{\text{Asp}}-\overset{\text{G}}{\text{Gly}}-\overset{\text{I}}{\text{Ile}}-\overset{\text{K}}{\text{Lys}}-\overset{\text{R}}{\text{Arg}}-\overset{\text{I}}{\text{Ile}}-\overset{\text{Q}}{\text{Gln}}-\overset{\text{D}}{\text{Asp}}-\overset{\text{D}}{\text{Asp}}-\text{COOH}$.

19. (Amended) A diagnostic test kit comprising a labeled monoclonal antibody, wherein said monoclonal antibody binds to the AT₁ subtype of the angiotensin II receptor, the antibody being produced by a hybridoma cell line deposited at European Collection of Animal Cell Cultures, Porton Down, UK under Accession No. 930720117.

New claims 20 and 21 are added, as follows:

Sub E1
D3
20. (New) A diagnostic test kit according to claim (18), wherein said label includes a compound selected from the group consisting of radioisotopes, enzymes, and fluorescent compounds.

21. (New) A diagnostic test kit according to claim 19, wherein said label includes a compound selected from the group consisting of radioisotopes, enzymes, and fluorescent compounds.

Sub
B1

Add
B1